“Effective pain management remains a significant challenge across multiple conditions. SBS-1000 has the potential to replace opioids for treating acute and chronic pain and could represent a critically needed innovation,” said Jeffrey B. Reich, MD, Chief Executive Officer, Sparian Biosciences.
NEW YORK (PRWEB)
February 23, 2023
Sparian Biosciences, Inc., a clinical-stage CNS-focused biopharmaceutical company, today announced the initiation of a phase 1 clinical trial of SBS-1000, its first-in-class arylepoxamide receptor (AEAr) agonist. SBS-1000 is the first AEAr agonist to receive IND clearance from the FDA and to proceed to a phase 1 human clinical study.
SBS-1000 targets the newly discovered AEA receptor (AEAr) in the pain pathway. In preclinical efficacy studies, SBS-1000 demonstrates potent analgesia in nociceptive, neuropathic, and inflammatory pain models. In addition, in preclinical safety studies, SBS-1000 does not demonstrate respiratory depression, physical dependence, or abuse liability compared to morphine.
“Effective pain management remains a significant challenge across medical and surgical conditions, and SBS-1000 has the potential to replace opioids for the treatment of acute and chronic pain. In the face of the ongoing opiate crisis, we believe SBS-1000 could represent a fundamental and critically needed innovation,” said Jeffrey B. Reich, MD, Chief Executive Officer, Sparian Biosciences. “We have been eager to start the phase 1 trial and hope that the promising preclinical profile of SBS-1000 will translate to human studies.”
The phase 1 clinical trial will primarily evaluate the safety, tolerability, and pharmacokinetics of SBS-1000. In addition, the compound’s analgesic efficacy will be assessed using the Cold Pressor Test as an exploratory endpoint. More details about the trial design will become available on http://www.clinicaltrials.gov.
About Sparian Biosciences
Sparian Biosciences is a clinical-stage CNS-focused biopharmaceutical company committed to developing transformational therapies to address significant medical needs. The company was co-founded by Jeff Reich, MD, and Gavril Pasternak, MD, PhD, and was spun out of Memorial Sloan Kettering Cancer Center (MSKCC). Sparian has five programs that address acute and chronic pain, opioid use disorder, acute opioid overdose, and stimulant use disorder. Sparian is the recipient of two NIH/ NIDA grants worth nearly $20 million. For more information, visit http://www.sparianbiosciences.com/.
Contact Information
Media
Karl Schmieder, Messaginglab
Karl@messaginglab.com
+1. 646.515.3392
Share article on social media or email: